This bill would change the Federal Food, Drug, and Cosmetic Act to permanently extend the Secretary of Health and Human Services' authority to award priority review vouchers for rare pediatric disease products. It does this by striking paragraph (5) of section 529(b) (21 U.S.C. 360ff(b)). The bill was introduced in the House on September 14, 2026, by Representative Gus Bilirakis and co-sponsors, and was referred to the House Committee on Energy and Commerce.
The bill makes the authority to award priority review vouchers for rare pediatric disease products permanent. No publicly available information on specific effects for patients, drug developers, or Food and Drug Administration processes is included in the bill text or metadata.
No publicly available information on costs, budgetary effects, or official cost estimates is included in the bill text or metadata.
No publicly available information in the bill text about proponents' stated reasons. Sponsors listed in the metadata include Gus Bilirakis, Nanette Barragán, Kat Cammack, Jake Auchincloss, Thomas Kean, and Kevin Mullin.
No publicly available information in the bill text or metadata about opponents' stated reasons or objections.